Group 1 - The core point of the article is that Changfeng Pharmaceutical Co., Ltd. (2652.HK) is raising approximately HKD 601 million through the issuance of 41.198 million shares at a price of HKD 14.75 per share, with the public offering accounting for 10% of the total shares [1] - The fundraising will allocate 40% of the proceeds to the ongoing research and development of inhalation formulation candidates and clinical development funding [1] - Approximately 20% of the funds will be used for preclinical research funding for multiple pipeline projects and technologies [1] - 30% of the proceeds will be directed towards equipment procurement and the expansion and upgrading of production management systems [1] Group 2 - Last year, Changfeng Pharmaceutical reported a revenue increase of 9% to nearly RMB 610 million, but net profit fell by 33.5% to RMB 21.09 million [1] - In the first quarter of this year, the company recorded a revenue of RMB 136 million, a year-on-year decrease of 2.7%, while net profit increased over twofold to RMB 12.815 million [1]
简讯：长风药业招股集资6亿港元
Xin Lang Cai Jing·2025-09-26 00:41